# Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer

> **NCT06421376** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Cancer
- Immunotherapy
- Induction Therapy
- Chemoradiotherapy
- Surgery

## Interventions

- **DRUG:** Cardonilizumab
- **RADIATION:** Chemoradiotherapy ±immunotherapy
- **PROCEDURE:** Radical surgery

## Key facts

- **NCT ID:** NCT06421376
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06421376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06421376, "Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06421376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*